Jinling Pharmaceutical Co Ltd Total Liabilities
Jinling Pharmaceutical Co Ltd total liabilities. Based on the latest financial reports, Jinling Pharmaceutical Co Ltd (000919) has total liabilities worth CN¥1.18 Billion CNY (≈ $172.22 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check 000919 financial resilience to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Jinling Pharmaceutical Co Ltd (1996–2024)
Total liabilities of Jinling Pharmaceutical Co Ltd from 1996 to 2024. This chart illustrates how Jinling Pharmaceutical Co Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore investment intensity of Jinling Pharmaceutical Co Ltd to see how much of total assets are deployed in long-term investments.
Jinling Pharmaceutical Co Ltd Competitors by Total Liabilities
The table below lists competitors of Jinling Pharmaceutical Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Groupe CRIT SA
PA:CEN
|
France | €875.15 Million |
|
Nextool Technology Co. Ltd. A
SHG:688419
|
China | CN¥216.86 Million |
|
Zhejiang Xinneng Photovoltaic Technology Co Ltd
SHG:603105
|
China | CN¥2.37 Billion |
|
Immix Biopharma Inc
NASDAQ:IMMX
|
USA | $10.19 Million |
|
Woori Technology Inc
KQ:032820
|
Korea | ₩196.54 Billion |
|
Northern United Publishing & Media Group Co Ltd
SHG:601999
|
China | CN¥1.41 Billion |
|
Hebei Sailhero Environmental
SHE:300137
|
China | CN¥338.32 Million |
|
Anhui Huaheng Biotechnology Co. Ltd. A
SHG:688639
|
China | CN¥3.36 Billion |
Liability Composition Analysis (1996–2024)
This chart breaks down Jinling Pharmaceutical Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see total assets of Jinling Pharmaceutical Co Ltd.
Liquidity & Leverage Metrics
Jinling Pharmaceutical Co Ltd Total Liabilities Ratios Explained
Jinling Pharmaceutical Co Ltd total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.69 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.31 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.20 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Jinling Pharmaceutical Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Jinling Pharmaceutical Co Ltd (1996–2024)
The table below shows the annual total liabilities of Jinling Pharmaceutical Co Ltd from 1996 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥1.24 Billion ≈ $181.49 Million |
+43.29% |
| 2023-12-31 | CN¥865.58 Million ≈ $126.66 Million |
-5.54% |
| 2022-12-31 | CN¥916.30 Million ≈ $134.08 Million |
+0.35% |
| 2021-12-31 | CN¥913.10 Million ≈ $133.61 Million |
+7.37% |
| 2020-12-31 | CN¥850.43 Million ≈ $124.44 Million |
+15.92% |
| 2019-12-31 | CN¥733.62 Million ≈ $107.35 Million |
+14.83% |
| 2018-12-31 | CN¥638.90 Million ≈ $93.49 Million |
-20.45% |
| 2017-12-31 | CN¥803.11 Million ≈ $117.52 Million |
-0.22% |
| 2016-12-31 | CN¥804.90 Million ≈ $117.78 Million |
-13.05% |
| 2015-12-31 | CN¥925.73 Million ≈ $135.46 Million |
+6.25% |
| 2014-12-31 | CN¥871.24 Million ≈ $127.49 Million |
+19.36% |
| 2013-12-31 | CN¥729.94 Million ≈ $106.81 Million |
-0.43% |
| 2012-12-31 | CN¥733.12 Million ≈ $107.28 Million |
+15.81% |
| 2011-12-31 | CN¥633.01 Million ≈ $92.63 Million |
+16.26% |
| 2010-12-31 | CN¥544.47 Million ≈ $79.67 Million |
+35.92% |
| 2009-12-31 | CN¥400.59 Million ≈ $58.62 Million |
+23.54% |
| 2008-12-31 | CN¥324.25 Million ≈ $47.45 Million |
-22.21% |
| 2007-12-31 | CN¥416.86 Million ≈ $61.00 Million |
+26.17% |
| 2006-12-31 | CN¥330.39 Million ≈ $48.35 Million |
+17.82% |
| 2005-12-31 | CN¥280.42 Million ≈ $41.03 Million |
-13.14% |
| 2004-12-31 | CN¥322.83 Million ≈ $47.24 Million |
+26.08% |
| 2003-12-31 | CN¥256.06 Million ≈ $37.47 Million |
-13.72% |
| 2002-12-31 | CN¥296.79 Million ≈ $43.43 Million |
-3.18% |
| 2001-12-31 | CN¥306.54 Million ≈ $44.86 Million |
+89.97% |
| 2000-12-31 | CN¥161.37 Million ≈ $23.61 Million |
+5.30% |
| 1999-12-31 | CN¥153.24 Million ≈ $22.42 Million |
+28.09% |
| 1998-12-31 | CN¥119.63 Million ≈ $17.51 Million |
+49.12% |
| 1997-12-31 | CN¥80.23 Million ≈ $11.74 Million |
+3.85% |
| 1996-12-31 | CN¥77.25 Million ≈ $11.30 Million |
-- |
About Jinling Pharmaceutical Co Ltd
Jinling Pharmaceutical Company Limited manufactures and sells pharmaceutical products in China and internationally. The company offers Mailuoning injection/oral solutions for the treatment of thromboangiitis obliterans, arteriosclerosis obliterans, cerebral thrombosis and sequelae, multiple arteriosclerosis, phlebitis, acute arterial embolism of the limbs, diabetic gangrene, venous thrombosis, an… Read more